EAACI Biologicals Guidelines

EAACI Biologicals Guidelines

Omalizumab for the treatment of chronic spontaneous urticaria in children and in adults

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost effectiveness still require further clarification.

The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

As a significant step in the creation of the EAACI Biologicals Guidelines, chapters are now being made available until 00:00 on 9 June 2021 for public review and commentary.

After feedback has been gathered, all the chapters, will be revised before publishing in autumn 2021.

We hereby invite all interested individuals, societies and stakeholders to study the documents and provide their valuable input via the dedicated online platform.

On behalf of EAACI, I wish to thank you very much for your valuable contribution to improve these important guidelines.  

Marek Jutel
EAACI President
Corresponding Author

Ioana Agache
EAACI Past President
Corresponding Author

Oscar Palomares
EAACI IG Representative
Corresponding Author


01. EAACI Biologicals Guidelines

Please click the View/Download button to view the Document in pdf format and then submit your feedback by clicking the Submit feedback button.
Submission has been closed.
Last updated 26 May 2021
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Send feedback